Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.60 |
| ▸ | HTR2A | P28223 | 15/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575454 | 0.94 | SLC6A2 (0.62) | SLC6A2HTR2AHTR2CHTR6MAPT | |
| SCHEMBL13544548 | 0.83 | SLC6A2 (0.49) | SLC6A2HTR2AHTR2CHTR6MAPT | |
| SCHEMBL3573500 | 0.82 | SLC6A2 (0.58) | SLC6A2HTR2AHTR2CHTR6MEN1 | |
| SCHEMBL320187 | 0.78 | NR3C1 (0.52) | MAPT | |
| SCHEMBL3569005 | 0.78 | SLC6A2 (0.73) | SLC6A2HTR2AHTR2CHTR6PTGER3 | |
| SCHEMBL3574952 | 0.78 | SLC6A2 (0.73) | SLC6A2HTR2AHTR2CHTR6PTGER3 | |
| SCHEMBL3573502 | 0.78 | SLC6A2 (0.63) | SLC6A2HTR2AHTR2CHTR6MAPT | |
| SCHEMBL4687106 | 0.78 | SLC6A2 (0.63) | SLC6A2HTR2AHTR2CHTR6MEN1 | |
| SCHEMBL3576872 | 0.77 | HTR6 (0.47) | SLC6A2HTR2AHTR2CHTR6MAPT | |
| SCHEMBL18926552 | 0.77 | PSMD10 (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645752-B2 | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors | WYETH LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645752-B2 | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors | WYETH LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645752-B2 | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors | WYETH LLC (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1973876-A2 | SULFONYL SUBSTITUTED 1H-INDOLES AS LIGANDS FOR THE 5-HYDROXYTRYPTAMINE RECEPTORS | Wyeth (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007084841-A2 | SULFONYL SUBSTITUTED 1H-INDOLES AS LIGANDS FOR THE 5-HYDROXYTRYPTAMINE RECEPTORS | WYETH (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203120-A1 | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | HTR5A, HTR2C, HTR2A | SLC6A2 20/4885HTR2A 3/4885HTR2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.